Feb 03, 2026 (MarketLine via COMTEX) --
Emilie Gauthy has been named Chief Technology Officer at Zelluna, effective immediately.
Zelluna (OSE: ZLNA), a company developing allogeneic off-the-shelf T-cell receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the appointment of Emilie Gauthy as Chief Technology Officer (CTO). Gauthy has been instrumental in building Zelluna's manufacturing and CMC capabilities since joining the company in 2022 and takes on the role with immediate effect.
In his role as CTO, Gauthy will continue to lead Zelluna's manufacturing and CMC strategy as the company develops its clinical program, scales up manufacturing capacity, and expands its portfolio of TCR-NK products.
Under Gauthy's leadership, Zelluna has established a scalable manufacturing process and analytical capabilities that enabled the successful submission of the company's Clinical Trial Application (CTA) for ZI-MA4-1 to the UK MHRA in December 2025. Key milestones include lock-in of the manufacturing process, production and quality testing of a GMP clinical batch, and establishment of the CMC basis for the company's first human clinical trial, with first data expected from mid-2026. These milestones underpin the entire TCR-NK platform and enable further development of future therapeutic products.
"Emilie has been instrumental in building the manufacturing and CMC capabilities that enabled us to submit our first CTA," said Namir Hassan, CEO of Zelluna. "Her appointment as CTO is a recognition of her leadership in establishing the foundation that has taken ZI-MA4-1 into clinical development and can be used to manufacture all of our future products."
"I am proud of what we have achieved as a team since 2022," says Emilie Gauthy, CTO of Zelluna. "Delivering our first CTA was an important milestone, and we have built a strong manufacturing foundation that enables further development of our platform. I look forward to supporting the clinical development of ZI-MA4-1 and further developing our pipeline."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_473348033/2227/2026-02-11T16:26:17
Copyright (C) 2026 Datamonitor. All rights reserved
